Associations - Rybrevant (amivantamab-vmjw)

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	amivantamab-vmjw Sensitive: A2 - Guideline amivantamab-vmjw Sensitive : A2	amivantamab-vmjw Sensitive: A2 - Guideline amivantamab-vmjw Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials amivantamab-vmjw + lazertinib Sensitive : B	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials amivantamab-vmjw + lazertinib Sensitive : B
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR L858R + MET positive	Non Small Cell Lung Cancer	EGFR L858R + MET positive	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3
EGFR exon 19 deletion + MET positive	Non Small Cell Lung Cancer	EGFR exon 19 deletion + MET positive	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3
EGFR S768_D770dup	Non Small Cell Lung Cancer	EGFR S768_D770dup	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4
EGFR H773delinsNPY	Non Small Cell Lung Cancer	EGFR H773delinsNPY	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4
EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification	Non Small Cell Lung Cancer	EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4	amivantamab-vmjw Sensitive: C4 – Case Studies amivantamab-vmjw Sensitive : C4
EGFR C797S + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	EGFR C797S + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D
EGFR T790M + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	EGFR T790M + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D
EGFR L858R + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	EGFR L858R + KRAS amplification + RB1 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D	amivantamab-vmjw Sensitive: D – Preclinical amivantamab-vmjw Sensitive : D
EGFR S768dupSVD	Non Small Cell Lung Cancer	EGFR S768dupSVD	Non Small Cell Lung Cancer	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D
EGFR A767dupASV	Non Small Cell Lung Cancer	EGFR A767dupASV	Non Small Cell Lung Cancer	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D	amivantamab-vmjw + mobocertinib Sensitive: D – Preclinical amivantamab-vmjw + mobocertinib Sensitive : D

Rybrevant (amivantamab-vmjw)

Associations
(25)

Associations
(25)

Rybrevant (amivantamab-vmjw)

Associations(25)

Associations(25)

Associations
(25)

Associations
(25)